Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer

Journal of Clinical Oncology

Volumn 12, Issue 8, 1994, Pages 1561-1571

  Welt, Sydney ^a   Divgi, Chaitanya R ^b   Kemeny, Nancy ^b   Finn, Ronald D ^b   Scott, Andrew M ^b   Graham, Martin ^b   St Germain, Jean ^b   Richards, Elizabeth Carswell ^b   Larson, Steven M ^b   Oettgen, Herbert F ^b   Old, Lloyd J ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CARCINOEMBRYONIC ANTIGEN; IODINE 131; MONOCLONAL ANTIBODY;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; DIAGNOSIS; DRUG CLEARANCE; DRUG TARGETING; FEMALE; HUMAN; IMMUNOSCINTIGRAPHY; INTRAVENOUS DRUG ADMINISTRATION; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY;

EID: 0027935133     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1994.12.8.1561     Document Type: Article

References (35)

1. Larson SM: Clinical radioimmunodetection, 1978-1988: Overview and suggestions for standardization of clinical trials. Cancer Res 50:892s-898s, 1990 (suppl)
2. Mach JP, Pelegrin A, Buchegger F: Imaging and therapy with monoclonal antibodies in non-hematopoietic tumors. Curr Opin Immunol 3:685-693, 1991
3. Sands H: Experimental studies of radioimmunodetection of cancer: An overview. Cancer Res 50:809s-813s, 1990
4. Goldenberg D: Future role of monoclonal antibodies in oncologic diagnosis and therapy. Semin Nucl Med 19:332-339, 1989
5. Halpern ES, Dillman RO: Problems associated with radioimmunodetection and possibilities for future solutions. J Biol Response Med 6:235-262, 1987
6. Epenetos AA, Snook D, Durbin H, et al: Limitations of radiolabeled monoclonal antibodies for localization of human neoplasms. Cancer Res 46:3183-3191, 1986
7. Colcher D, Esteban JM, Carrasquillo JA, et al: Quantitative analyses of selective radiolabeled monoclonal antibody localization metastatic lesions of colorectal cancer patients. Cancer Res 47:1185-1189, 1987
8. Cohn KH, Welt S, Banner WP, et al: Localization of radioiodinated monoclonal antibody in colorectal cancer. Arch Surg 122:1425-1429, 1987
9. 2 fragments from monoclonal anti-carcinoembryonic antigen antibodies. J Clin Invest 77:301-311, 1986
10. 2 fragments of anti-CEA monoclonal antibody. Cancer Detect Prev 10:335-345, 1987
11. Larson SM, Divgi C, Scott A, et al: Current status of radioimmunodetection. Nucl Med Biol (in press)
12. Welt S, Divgi CR, Real FX, et al: Quantitative analysis of antibody localization in human metastatic colon cancer: A phase I study with monoclonal antibody A33. J Clin Oncol 8:1894-1906, 1990
13. Koizumi K, DeNardo GL, DeNardo SJ, et al: Multicompartmental analysis of the kinetics of radioiodinated monoclonal antibody in patients with cancer. J Nucl Med 27:1243-1254, 1986
14. Zanzonico PB, Bigler RE, Primus FJ, et al: A compartmental modeling approach to the radiation dosimetry of radiolabeled antibody, in Schlafke-Stelson AT, Watson EE (eds): Proceedings of the Fourth International Dosimetry Symposium, Oak Ridge, TN, November 5-8, 1985. US Dept. of Energy and Oak Ridge-Associated Universities (Conf 85113 [DC 86010102]), 1986, pp 421-455
15. Griffith MH, Yorke ED, Wessels BW, et al: Direct dose confirmation of quantitative autoradiography with micro-TLD measurements for radioimmunotherapy. J Nucl Med 29:1795-1809, 1988
16. Pentlow KS, Graham MC, Lambrecht RM, et al: Quantitative imaging of 1-124 using positron emission tomography with applications to radioimmunodiagnosis and radioimmunotherapy. Med Phys 18:357-366, 1991
17. 131I-monoclonal antibody (mAb) A33 in patients with advanced colorectal carcinoma. Proc Am Soc Clin Oncol 11:169, 1992 (abstr 489)
18. 131I-monoclonal antibody A33. Proc Am Assoc Cancer Res 34:477. 1993 (abstr 2844)
19. Siegel JA, Wessels BW, Watson EE, et al: Bone marrow dosimetry and toxicity for radioimmunotherapy. Antibody Immunoconj Radiopharmacol 3:213-233, 1990
20. Badger C: Bone marrow toxicity for I-131 labeled antibodies. Antibody Immunoconjugate Radiopharmacology 3:281-287, 1990
21. Sgouros G: Bone marrow dosimetry for radioimmunotherapy: Theoretical considerations. J Nucl Med 34:689-694, 1993
22. Bradwell AR, Vaughan A, Fairweather DS, Dykes PW: Improved radioimmunodetection of tumours using second antibody. Lancet 1:247, 1983 (letter)
23. Sharkey RM, Primus FJ, Goldenberg DM: Second antibody clearance of radiolabeled antibody in cancer radioimmunodetection. Proc Natl Acad Sci USA 81:2843-2846, 1984
24. 2 fragments. Cancer Res 45:3378-3387, 1985
25. Colcher D, Bird R, Roselli M, et al: In vivo tumor targeting of a recombinant single-chain antigen-binding protein. J Natl Cancer Inst 82:1191-1197, 1990
26. Epenetos AA, Munro AJ, Stewart S, et al: Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabeled monoclonal antibodies. J Clin Oncol 5:1890-1899, 1987
27. Colcher D, Esteban J, Carrasquillo JA, et al: Complementation of intracavitary and intravenous administration of a monoclonal antibody (B72.3) in patients with carcinoma [published erratum appears in Cancer Res 47:6161, 1987]. Cancer Res 47:4218-4224, 1987
28. 131I conjugated monoclonal antibody CC49: A phase I trial. Antibody Immunoconj Radiopharmacol 6:90, 1993 (abstr 84)
29. Sastry KSR: Biological effects of the Auger emitter iodine-125: A review. Report No. 1 of AAPM Nuclear Medicine Task Group No. 6. Med Phys 19:1361-1370, 1992
30. Brady LW, Miyamoto C, Woo DV, et al: Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: A phase II trial. Int J Radiat Oncol Biol Phys 22:225-230, 1991
31. Winter G, Milstein C: Man-made antibodies. Nature 349:293-299, 1991
32. Hird V, Verhoyen M, Badley RA, et al: Tumour localisation with a radioactively labelled reshaped human monoclonal antibody. Br J Cancer 64:911-914, 1991
33. Fowler JF: Brief summary of radiobiological principles in fractionated radiotherapy. Semin Radiat Oncol 2:16-21, 1992
34. Fowler JF: Intercomparisons of new and old schedules in fractionated radiotherapy. Semin Radiat Oncol 2:67-72, 1992
35. Thames HD Jr, Withers HR, Peters LJ, Fletcher GH: Changes in early and late radiation responses with altered dose fractionation: Implications for dose-survival relationship. Int J Radiat Oncol Biol Phys 8:219-226, 1992